Supernus Pharmaceuticals | SUPN - Current Liabilities


Supernus Pharmaceuticals reported $285.4M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Abbott USD 16.15B 1.66B Sep/2026
ANI Pharmaceuticals USD 328.72M 45.06M Sep/2026
Aurora Cannabis CAD 73.43M 6.5M Jun/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Canopy Growth CAD 166.75M 8.31M Jun/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Corcept Therapeutics USD 177.68M 23.87M Sep/2026
Eisai JPY 371.5B 22.14B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Pacira USD 126.1M 4.08M Sep/2026
Perrigo USD 1.02B 34.4M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Supernus Pharmaceuticals USD 285.4M 61.98M Sep/2026
United Therapeutics USD 624.3M 16.5M Sep/2026
Xeris Pharmaceuticals USD 134.48M 55.09M Sep/2026